ACCESS PACK EXPO XPRESS ONLINE TODAY. Content is available on-demand through November 30th.

FDA Restricts J&J COVID-19 Vaccine

A possible risk of a blood clotting condition has led the agency to apply strict limits on the single-shot vaccine.

Screen Shot 2022 04 18 At 2 48 25 Pm
Getty Images

A recent CNN Health article discussed the recent limitations placed on Johnson & Johnson’s COVID-19 vaccine. Last week, the FDA dialed back its emergency use authorization for people 18 and older. A statement released by the agency cited a possible risk of thrombosis with thrombocytopenia syndrome, a rare blood clotting condition, after vaccination. Despite this, the FDA believes the benefits of the J&J vaccine still outweigh the risk for certain people, including:

  • Those who had a severe allergic reaction to an mRNA vaccine such as those from Pfizer/BioNTech or Moderna
  • Those with personal concerns about the mRNA vaccines who would remain unvaccinated without the J&J vaccine
  • Those with limited access to mRNA Covid-19 vaccines

Thus far, nearly 19 million doses of the vaccine have been administered in the U.S., accounting for 7.7% of fully vaccinated people.

Access On-Demand Content Today
Discover innovative solutions for packaging and processing, automation, sustainability, e-commerce and more.
Access On-Demand Content Today
Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Take Quiz
Test Your Supply Chain Smarts